Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 18 clinical trials
A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Activating mutations in the fms like tyrosine kinase 3 (FLT3) gene are observed in approximately 30% of patients with newly diagnosed acute myeloid leukemia (AML). Addition of the multitargeted kinase inhibitor midostaurin to standard chemotherapy prolongs event-free survival (EFS) and overall survival (OS) in patients with a FLT3 mutation. Gilteritinib …

consolidation chemotherapies
hematologic disorder
tyrosine
serum bilirubin level
myelodysplastic syndromes
  • 10 views
  • 23 Jan, 2021
  • 1 location
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2 With an IDH1 or IDH2 Mutation Respectively Eligible for Intensive Chemotherapy

AML and MDS-EB2 are malignancies of the bone marrow. The standard treatment for these diseases is chemotherapy. Patients participating have a special type of this disease because the leukemia cells (blasts) have developed an error in the genetic material (DNA). This error is called an IDH1 mutation or an IDH2 …

hematologic disorder
IDH2
cancer
enasidenib
consolidation therapy
  • 13 views
  • 23 Jan, 2021
  • 1 location
G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1 REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

. In this prospective study, the safety and efficacy of G-CSF+DAC+BUCY and G-CSF+DAC+BF conditioning regimens in RAEB-1, REAB-2 and AML secondary to MDS undergoing allo-HSCT are evaluated.

  • 0 views
  • 29 Jan, 2021
  • 1 location
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10) followed by donor stem cell transplant in treating patients with high-risk acute leukemia or myelodysplastic syndrome that has come back (recurrent) or isn't responding to treatment (refractory). 211At-BC8-B10 is a …

cell transplantation
total body irradiation
anti-cd45 monoclonal antibody bc8
acute leukemia
hla-a
  • 0 views
  • 11 Apr, 2021
  • 1 location
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

enasidenib
anemia
decitabine
serum bilirubin level
sgi-110
  • 10 views
  • 29 Jan, 2021
  • 8 locations
Fludarabine Phosphate Cytarabine Filgrastim-sndz Gemtuzumab Ozogamicin and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

This phase II trial studies the side effects and how well fludarabine phosphate, cytarabine, filgrastim-sndz, gemtuzumab ozogamicin, and idarubicin hydrochloride work in treating patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as fludarabine phosphate, cytarabine, and idarubicin hydrochloride, work in different ways …

cytarabine
raeb
filgrastim
anemia
idarubicin
  • 24 views
  • 07 May, 2021
  • 1 location
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

RATIONALE: Giving chemotherapy, such as busulfan, fludarabine, and melphalan, before a donor umbilical cord blood stem cell transplant helps stop the growth of abnormal or cancer cells and prepares the patient's bone marrow for the stem cells. When the healthy stem cells from a donor are infused into the patient …

filgrastim
acute leukemia
granulocyte colony stimulating factor
anemia
lymphoid leukemia
  • 37 views
  • 29 Jan, 2021
  • 1 location
CPX-351 Versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers With Measurable Residual Disease

This phase II trial studies the effect of CPX-351 followed by donor stem cell transplantation versus immediate donor stem cell transplantation in treating patients with high-grade myeloid cancers with measurable residual disease. Chemotherapy drugs, such as CPX-351, work in different ways to stop the growth of tumor cells, either by …

  • 0 views
  • 02 May, 2021
  • 1 location
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Myelodysplastic Syndrome or Mixed-Phenotype Acute Leukemia

This phase I/II trial studies the side effects and best dose of 211^astatine(At)-BC8-B10 before donor stem cell transplant in treating patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or mixed-phenotype acute leukemia. Radioactive substances, such as astatine-211, linked to monoclonal antibodies, such as BC8, can bind to …

cell transplantation
total body irradiation
leukemia, acute lymphoblastic
acute leukemia
hla-a
  • 19 views
  • 08 Mar, 2021
  • 1 location
Cord Blood Transplant With OTS for the Treatment of HIV Positive Hematologic Cancers

This phase II trial studies the side effects of a cord blood transplant using OTS and to see how well it works in treating patients with human immunodeficiency virus (HIV) positive hematologic (blood) cancers. After a cord blood transplant, the immune cells, including white blood cells, can take a while …

  • 0 views
  • 30 Apr, 2021
  • 5 locations